TURKU, FI / ACCESS Newswire / May 28, 2026 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN)
Standard form for notification of major holdings
|
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FIN-FSA) |
|||||
|
1. Identity of the issuer: |
|||||
|
2. Reason for the notification (please tick the appropriate box or boxes): ☐ An acquisition or disposal of shares or voting rights |
|||||
|
3. Details of person subject to the notification obligation: |
|||||
|
Name: |
City and country of residence: |
||||
|
4. Full name of shareholder(s) (if different from 3.): |
|||||
|
5. Date on which the threshold was crossed or reached: |
|||||
|
6. Total positions of person(s) subject to the notification obligation: |
|||||
|
% of shares and voting rights |
% of shares and voting rights through financial instruments |
Total of both in % (7.A + 7.B) |
Total number of shares and voting rights of issuer |
||
|
Resulting situation on the date on which threshold was crossed or reached |
0.10 |
9.36 |
9.46 |
203,045,511 |
|
|
Position of previous notification (if applicable) |
n/a |
n/a |
n/a |
||
|
7. Notified details of the resulting situation on the date on which the threshold was crossed or reached: |
|||||||||
|
A: Shares and voting rights |
|||||||||
|
Class/type of |
Number of shares and voting rights |
% of shares and voting rights |
|||||||
|
Direct |
Indirect |
Direct |
Indirect |
||||||
|
FI4000153309 |
0 |
207,708 |
0 |
0.10 |
|||||
|
– |
– |
– |
– |
– |
|||||
|
– |
– |
– |
– |
– |
|||||
|
SUBTOTAL A |
207,708 |
0.10 |
|||||||
|
B: Financial Instruments according to SMA 9:6a |
|||||||||
|
Type of financial instrument |
Expiration |
Exercise/ |
Physical or cash settlement |
Number of shares and voting rights |
% of shares and voting rights |
||||
|
Rights of Use |
n/a |
n/a |
n/a |
18,798,276 |
9.26 |
||||
|
Swaps |
15/10/2027 |
n/a |
Cash |
201,276 |
0.10 |
||||
|
SUBTOTAL B |
18,999,552 |
9.36 |
|||||||
|
|
|||||||||
|
8. Information in relation to the person subject to the notification obligation (please tick the applicable box): ☐ Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer. ☒ Full chain of controlled undertakings through which the voting rights and/or the |
|||
|
Name |
% of shares and voting rights |
% of shares and voting rights through financial instruments |
Total of both |
|
Bank of America Corporation |
Click here to enter text. |
Click here to enter text. |
Click here to enter text. |
|
NB Holdings Corporation |
Click here to enter text. |
Click here to enter text. |
Click here to enter text. |
|
BofAML Jersey Holdings Limited |
Click here to enter text. |
Click here to enter text. |
Click here to enter text. |
|
BofAML EMEA Holdings 2 Limited |
Click here to enter text. |
Click here to enter text. |
Click here to enter text. |
|
ML UK Capital Holdings Limited Merrill Lynch International Bank of America Corporation NB Holdings Corporation BAC North America Holding Company Bank of America, National Association Bank of America Corporation NB Holdings Corporation BofA Securities, Inc |
Click here to enter text. |
9.26% |
9.26% |
|
9. In case of proxy voting: [name of the proxy holder] will cease to hold [% and number] voting rights as of Click here to enter a date. |
|||
|
10. Additional information: |
|||
Done at London, United Kingdom on 27.5.2026.
SOURCE: Faron Pharmaceuticals
View the original press release on ACCESS Newswire
Media gallery
